Threshold Pharmaceuticals, Inc (THLD): Opiniones

pedazo rebote en los 6$.
Alguien ha comprado y ha pillado a 6??????????

Yo. Eso es buy puro...

Ya, pero cuando me he conectado ya estaba en 6.veintipico.
buena compra.

"Compra de hierro" en castelano-bursatil-antiguo-del-copon!

Estoy seguro que en cuanto se sepa algo bueno por parte de la compañia nos vamos a los 7$ y también estoy seguro que se sabrá. Una posibilidad es ASCO pero es un congreso médico, no de inversores, por eso que nadie espere que demos el salto por encima de 7-8$
Algo si vamos a subir, pero no estratosférico.

PD. Hoy estoy de huelga.

Buenos dias
Alguien que pueda descifrar esto? Me enviaro la alerta ayer a la noche:
http://investor.thresholdpharm.com/secfiling.cfm?filingid=1225208-12-12886
saludos

Entropizado, es una notificación de transacción en forma de 20.000 stock options a nombre del Director. Lo que no tengo claro es si las compra, las vende o ambas dos. En cualquier caso, es normal retribuir al consejo de administración de este forma en empresas de este tipo.

Saludos.

http://www.thestreet.com/r/ratings/reports/analysis/THLD.html

TRADE WITH JIM CRAMER
Try Action Alerts PLUS - FREE

BERT DOHMEN ON MARKETS

HOMEMARKETSHAPPENING NOWRESEARCHSTOCK PICKSTECHWEALTHLIVINGSMALL BUSINESSVIDEOSPREMIUM SERVICES
HOT TOPICS:
MLPs in IRA
Yahoo vs. Facebook
Stock Futures
Stocks to Watch
Gold Rally
Hated Stocks
Kass
JPMorgan
Biopharma Breakouts

Research Center
Reports
Stock Upgrades & Downgrades
Threshold Pharmaceuticals Inc.
THLD : NASDAQ : Health Care
Stockpickr ETFs Holding THLD

Find Ratings Reports
$6,37
0,26 | 4,26%
Today's Range: 6,00 - 6,43
Avg. Daily Volume: 3.382.000
05/21/12 - 4:00 PM ET
TRADE NOW
Rating Summary Rating Detail Financial Analysis Peer Group
Financial Analysis

THRESHOLD PHARMACEUTICALS's gross profit margin for the first quarter of its fiscal year 2012 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. THRESHOLD PHARMACEUTICALS is extremely liquid. Currently, the Quick Ratio is 5.74 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 478.12% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

INCOME STATEMENT Q1 FY12 Q1 FY11
Net Sales ($mil) 0.25 0.0
EBITDA ($mil) -7.12 -7.31
EBIT ($mil) -7.14 -7.39
Net Income ($mil) -115.53 -8.33

BALANCE SHEET Q1 FY12 Q1 FY11
Cash & Equiv. ($mil) 49.73 38.37
Total Assets ($mil) 89.71 39.8
Total Debt ($mil) 0.0 0.0
Equity ($mil) -77.45 20.48

PROFITABILITY Q1 FY12 Q1 FY11
Gross Profit Margin -2825.4 0.0
EBITDA Margin -2825.4 0.0
Operating Margin -2834.52 0.0
Sales Turnover 0.0 0.0
Return on Assets -148.09 -52.9
Return on Equity 0.0 -102.79
DEBT Q1 FY12 Q1 FY11
Current Ratio 5.79 8.49
Debt/Capital 0.0 0.0
Interest Expense 0.0 0.0
Interest Coverage 0.0 0.0

SHARE DATA Q1 FY12 Q1 FY11
Shares outstanding (mil) 54.1 48.8
Div / share 0.0 0.0
EPS -2.3 -0.23
Book value / share -1.43 0.42
Institutional Own % n/a n/a
Avg Daily Volume 3383281.0 1031841.0

Valuation

SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium.

PRICE/EARNINGS
1 2 3 4 5
PREMIUM   DISCOUNT   PRICE/CASH FLOW
1 2 3 4 5
PREMIUM   DISCOUNT
THLD NM Peers 30.10   THLD NM Peers 23.92
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.THLD's P/E is negative making this valuation measure meaningless.   Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.THLD's P/CF is negative making the measure meaningless.
 
PRICE/PROJECTED
EARNINGS
1 2 3 4 5
PREMIUM   DISCOUNT   PRICE TO
EARNINGS/GROWTH
1 2 3 4 5
PREMIUM   DISCOUNT
THLD NM Peers 28.77   THLD NA Peers 0.85
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.THLD's ratio is negative making this valuation measure meaningless.   Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.Ratio not available.
 
PRICE/BOOK
1 2 3 4 5
PREMIUM   DISCOUNT   EARNINGS GROWTH
1 2 3 4 5
LOWER   HIGHER
THLD NM Peers 16.55   THLD -334.42 Peers 15.79
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.THLD's P/B is negative making this valuation measure meaningless.   Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.However, THLD is expected to significantly trail its peers on the basis of its earnings growth rate.
 
PRICE/SALES
1 2 3 4 5
PREMIUM   DISCOUNT   SALES GROWTH
1 2 3 4 5
PREMIUM   DISCOUNT
THLD 1101.72 Peers 17.89   THLD NA Peers 69.59
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.THLD is trading at a significant premium to its industry.   Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.The growth rate for THLD is not available.